The broad, long-term objectives and specific aims are to increase hematopoietic cell donor availability, progression free and overall survival following allogeneic hematopoietic cell transplantation (HCT) for malignant diseases. One major obstacle for HCT is the lack of a suitable donor. We have developed a non myeloablative regimen that is the first step or platform in a process of graft engineering that will allow us to add other "building blocks" for a more successful graft. Our results suggest that this alemtuzumab based non myeloablative regimen allows engraftment with low morbidity and treatment related mortality, allowing older, more infirmed patients to undergo allogeneic HCT. The primary limitations to greater success are relapse and delayed immune recovery. The central hypothesis of this project is that we will be able to engineer a graft that allows engraftment without graft versus host disease (GVHD). We will then build in a post transplant strategy to enhance anti tumor responses. Several complementary projects will be pursued in order to test this hypothesis. In the first aim, we will complete the feasibility study and early immune reconstitution analyses to provide a foundation and then focus on a larger phase II study enrolling better risk patients to confirm our initial observations.
This aim will be the foundation for the additional graft enhancements in Aims 2-4 and projects I, II, and III.
In Aim 2, we will continue our initial studies of addition of donor natural killer cell (NK) infusions following HCT and monitor immune responses against the tumor and overall immune recovery.
Aim 3 will begin our first series of studies using WT-1 as a target in hematolymphoid diseases. This first study of WT-1 will be the foundation for us to build upon additional strategies aimed at this tumor specific antigen.
Aim 4 will be to carry out a clinical study with the use of TLR ligands (initially CpG) along with Project III. This project will also serve as the information center for the early phase I studies that will be carried out in Project II. Each clinical study is supported by Cores A &B. The correlative analyses from each study are supplied by Core C. Thus this project serves as the clinical research for the other projects and interacts extensively with all three cores. The lessons learned from these trials will set the stage for future studies aimed at decreasing GVHD and relapse and improving long term survival.
|Brunger, Jonathan M; Huynh, Nguyen P T; Guenther, Caitlin M et al. (2014) Scaffold-mediated lentiviral transduction for functional tissue engineering of cartilage. Proc Natl Acad Sci U S A 111:E798-806|
|Kanda, Junya; Long, Gwynn D; Gasparetto, Cristina et al. (2014) Reduced-intensity allogeneic transplantation using alemtuzumab from HLA-matched related, unrelated, or haploidentical related donors for patients with hematologic malignancies. Biol Blood Marrow Transplant 20:257-63|
|Brandstadter, Joshua D; Huang, Xiaopei; Yang, Yiping (2014) NK cell-extrinsic IL-18 signaling is required for efficient NK-cell activation by vaccinia virus. Eur J Immunol 44:2659-66|
|Macintyre, Andrew N; Gerriets, Valerie A; Nichols, Amanda G et al. (2014) The glucose transporter Glut1 is selectively essential for CD4 T cell activation and effector function. Cell Metab 20:61-72|
|Horwitz, Mitchell E; Chao, Nelson J; Rizzieri, David A et al. (2014) Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment. J Clin Invest 124:3121-8|
|Glass, Katherine A; Link, Jarrett M; Brunger, Jonathan M et al. (2014) Tissue-engineered cartilage with inducible and tunable immunomodulatory properties. Biomaterials 35:5921-31|
|Chen, Benny J; Jiao, Yiqun; Zhang, Ping et al. (2013) Long-term in vivo imaging of multiple organs at the single cell level. PLoS One 8:e52087|
|Kanda, J; Kaynar, L; Kanda, Y et al. (2013) Pre-engraftment syndrome after myeloablative dual umbilical cord blood transplantation: risk factors and response to treatment. Bone Marrow Transplant :|
|Fortin, Carl; Huang, Xiaopei; Yang, Yiping (2013) Both NK cell-intrinsic and -extrinsic STAT1 signaling are required for NK cell response against vaccinia virus. J Immunol 191:363-8|
|Kanda, J; Horwitz, M E; Long, G D et al. (2012) Outcomes of a 1-day nonmyeloablative salvage regimen for patients with primary graft failure after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 47:700-5|
Showing the most recent 10 out of 92 publications